Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment By Ogkologos - June 16, 2026 98 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-9 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Second Interim Analysis Shows OS Improvement with Adjuvant Olaparib for Germline... October 12, 2022 Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial September 23, 2021 A radical project: video game design meets cancer research December 1, 2022 Real-World Increase in Biomarker Testing in Lung Cancer Patients, Registry Study... March 23, 2022 Load more HOT NEWS An Updated Overview of Estimates for Cancer Incidence and Mortality in... A career forged in team science Real-World Patients with Cancer Show Lower Survival Times and Treatment-Associated Survival... FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease
